Acta Neuropathologica

, 116:147 | Cite as

TDP-43-negative FTLD-U is a significant new clinico-pathological subtype of FTLD

  • Sigrun Roeber
  • Ian R. A. Mackenzie
  • Hans A. Kretzschmar
  • Manuela Neumann
Original Paper

Abstract

Frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) is the most common neuropathological subtype of frontotemporal dementias. While TDP-43 is the pathologic protein in the majority of FTLD-U cases, small numbers of cases have recently been reported with TDP-43-negative FTLD-U pathology. To determine the frequency and to define the clinico-pathological spectrum of TDP-43-negative FTLD-U, we re-evaluated 44 cases with a previous diagnosis of FTLD-U or dementia lacking distinctive histopathology. We identified nine cases (20%) with TDP-43-negative FTLD-U pathology by immunohistochemistry and confirmed the absence of pathological TDP-43 by biochemical analysis. All patients presented with sporadic early-onset frontotemporal dementia with predominant behavioral and personality changes. Besides ubiquitin-positive neuronal cytoplasmic inclusions, the most intriguing neuropathological feature was the presence of ubiquitin-positive neuronal intranuclear inclusions (NIIs), often with curved or twisted morphology, in the neocortex, hippocampus, brainstem, and spinal cord. Double-label immunofluorescence revealed an unusual and distinct immunoreactivity profile for these NIIs, with ubiquitin-immunoreactivity, but absence of p62 labeling. The highly consistent clinical and neuropathological phenotype supports the concept that TDP-43-negative FTLD-U should be considered as a new clinicopathological FTLD entity.

Keywords

TDP-43 p62 Ubiquitin Intranuclear inclusions Frontotemporal dementia Frontotemporal lobar degeneration 

Notes

Acknowledgment

The work was supported by grants from the German Federal Ministry of Education and Research (BrainNet 01GI0505), the Canadian Institutes of Health Research (grant # 74580) and the Pacific Alzheimer Research Foundation. We are very grateful to I. Pigur for expert technical assistance histological processing. We thank all the collaborating clinics and the donors and families of patients who made this study possible.

References

  1. 1.
    Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R et al (2007) TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer’s disease. Ann Neurol 61:435–445PubMedCrossRefGoogle Scholar
  2. 2.
    Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H et al (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351:602–611. doi: 10.1016/j.bbrc.2006.10.093 PubMedCrossRefGoogle Scholar
  3. 3.
    Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ et al (2007) Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the consortium for frontotemporal lobar degeneration. Acta Neuropathol 114:5–22. doi: 10.1007/s00401-007-0237-2 PubMedCrossRefGoogle Scholar
  4. 4.
    Cairns NJ, Neumann M, Bigio EH, Holm IE, Troost D, Hatanpaa KJ et al (2007) TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol 171:227–240. doi: 10.2353/ajpath.2007.070182 PubMedCrossRefGoogle Scholar
  5. 5.
    Davidson Y, Kelley T, Mackenzie IR, Pickering-Brown S, Du Plessis D, Neary D et al (2007) Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathol 113:521–533. doi: 10.1007/s00401-006-0189-y PubMedCrossRefGoogle Scholar
  6. 6.
    Giannakopoulos P, Hof PR, Bouras C (1995) Dementia lacking distinctive histopathology: clinicopathological evaluation of 32 cases. Acta Neuropathol 89:346–355. doi: 10.1007/BF00309628 PubMedCrossRefGoogle Scholar
  7. 7.
    Grossman M (2002) Frontotemporal dementia: a review. J Int Neuropsychol Soc 8:566–583. doi: 10.1017/S1355617702814357 PubMedCrossRefGoogle Scholar
  8. 8.
    Hatanpaa KJ, Bigio EH, Cairns NJ, Womack KB, Weintraub S, Morris JC et al (2008) TAR DNA-binding protein 3 immunohistochemistry reveals extensive neuritic pathology in FTLD-U: a midwest–southwest consortium for FTLD study. J Neuropathol Exp Neurol 67:271–279. doi: 10.1097/NEN.0b013e31816a12a6 PubMedCrossRefGoogle Scholar
  9. 9.
    Johnson JK, Diehl J, Mendez MF, Neuhaus J, Shapira JS, Forman M et al (2005) Frontotemporal lobar degeneration: demographic characteristics of 353 patients. Arch Neurol 62:925–930. doi: 10.1001/archneur.62.6.925 PubMedCrossRefGoogle Scholar
  10. 10.
    Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Schindzielorz A et al (2000) Subcellular localization of wild-type and Parkinson’s disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J Neurosci 20:6365–6373PubMedGoogle Scholar
  11. 11.
    Knopman DS, Mastri AR, Frey WH, Sung JH, Rustan T (1990) Dementia lacking distinctive histologic features: a common non-Alzheimer degenerative dementia. Neurology 40:251–256PubMedGoogle Scholar
  12. 12.
    Kuusisto E, Salminen A, Alafuzoff I (2001) Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. Neuroreport 12:2085–2090. doi: 10.1097/00001756-200107200-00009 PubMedCrossRefGoogle Scholar
  13. 13.
    Lipton AM, White CL 3rd, Bigio EH (2004) Frontotemporal lobar degeneration with motor neuron disease-type inclusions predominates in 76 cases of frontotemporal degeneration. Acta Neuropathol 108:379–385. doi: 10.1007/s00401-004-0900-9 PubMedCrossRefGoogle Scholar
  14. 14.
    Mackenzie IR, Foti D, Woulfe J, Hurwitz TA (2008) Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions. Brain 131:1282–1293. doi: 10.1093/brain/awn061 PubMedCrossRefGoogle Scholar
  15. 15.
    Mackenzie IR, Shi J, Shaw CL, Duplessis D, Neary D, Snowden JS et al (2006) Dementia lacking distinctive histology (DLDH) revisited. Acta Neuropathol 112:551–559. doi: 10.1007/s00401-006-0123-3 PubMedCrossRefGoogle Scholar
  16. 16.
    Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S et al (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51:1546–1554PubMedGoogle Scholar
  17. 17.
    Neumann M, Igaz LM, Kwong LK, Nakashima-Yasuda H, Kolb SJ, Dreyfuss G et al (2007) Absence of heterogeneous nuclear ribonucleoproteins and survival motor neuron protein in TDP-43 positive inclusions in frontotemporal lobar degeneration. Acta Neuropathol 113:543–548. doi: 10.1007/s00401-007-0221-x PubMedCrossRefGoogle Scholar
  18. 18.
    Neumann M, Kwong LK, Truax AC, Vanmassenhove B, Kretzschmar HA, Van Deerlin VM et al (2007) TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. J Neuropathol Exp Neurol 66:177–183. doi: 10.1097/01.jnen.0000248554.45456.58 PubMedCrossRefGoogle Scholar
  19. 19.
    Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130–133. doi: 10.1126/science.1134108 PubMedCrossRefGoogle Scholar
  20. 20.
    Pickering-Brown SM (2007) The complex aetiology of frontotemporal lobar degeneration. Exp Neurol 206:1–10. doi: 10.1016/j.expneurol.2007.03.017 PubMedCrossRefGoogle Scholar
  21. 21.
    Pikkarainen M, Hartikainen P, Alafuzoff I (2008) Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions visualized with ubiquitin-binding protein p62 immunohistochemistry. J Neuropathol Exp Neurol 67:280–298PubMedCrossRefGoogle Scholar
  22. 22.
    Probst A, Taylor KI, Tolnay M (2007) Hippocampal sclerosis dementia: a reappraisal. Acta Neuropathol 114:335–345. doi: 10.1007/s00401-007-0262-1 PubMedCrossRefGoogle Scholar
  23. 23.
    Shi J, Shaw CL, Du Plessis D, Richardson AM, Bailey KL, Julien C et al (2005) Histopathological changes underlying frontotemporal lobar degeneration with clinicopathological correlation. Acta Neuropathol 110:501–512. doi: 10.1007/s00401-005-1079-4 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Sigrun Roeber
    • 1
  • Ian R. A. Mackenzie
    • 2
  • Hans A. Kretzschmar
    • 1
  • Manuela Neumann
    • 1
  1. 1.Center for Neuropathology and Prion ResearchLudwig-Maximilians University MunichMunichGermany
  2. 2.Department of Pathology and Laboratory MedicineUniversity of British ColumbiaVancouverCanada

Personalised recommendations